Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Wealth creation)

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 16:12 Detailed Submission 2 comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”

Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its is so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.
 
Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 3 years of development, research, testing and clinical trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further clinical trials will be starting shortly with Cardiff University.
 
Airglove is registered with the MHRA and Certified as a Medical Device.

 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.
 
Data regarding patient experience and resource savings are being collected as part of the patient evaluation trials at Maidstone and Tunbridge Wells Hospital. Evidence from trials undertaken to date appears to support these benefits.
 
Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.
 
Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.
 
“I felt compelled to come up with the original concept which became Airglove in response to cancer patients’ needs when I was General Manager at Maidstone and Tunbridge Wells NHS Trust. My aim was to improve health and safety standards and deliver efficiencies in healthcare worldwide.”
Paula Tinniswood – Healthcare, Transformation & Improvement Consultant
 
“In a 20 bed unit at Maidstone and Tunbridge Wells NHS Trust hospital we have 80 patients per day with 30 to 40 of them require heating before cannulation”.
Keli Tomlin, Macmillian Lead Chemotherapy Nurse – Chemotherapy Unit, The Maidstone and Tunbridge Wells NHS Hospital Trust
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having an oncology department.
 
Current and planned activity: 
Current activity:
Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. It is in currently undergoing patient evaluation trials with the Oncology department at MTW.
 
We are also working with Cardiff University to undertake additional clinical trials, along with registering Airglove with the NICE Medical Technologies Evaluation Programme.

Maidstone & Tunbridge Wells NHS Trust are currently using the Airglove.

Planned activity:
The first production of Airglove Unit and gloves will be available by 30/4/17. A few from the first production will be made available on loan free to hospitals who wish to undertake collaborative patient trials.
 
We would welcome patient trials partners from hospitals and clinics within the West Midlands region.
 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.


Airglove is protected by International patents some of which have been granted and others are in the application stage via Murgitroyd Patent Attorneys.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Airglove is registered with the MHRA as a Class 1 Medical Device and is CE marked.
 
The first batch of production Airgloves will be issued with a new medical devices certificate (CE EN60601-01 EN60601-1-2 2007).
Commercial information:
Please see attached for target market/demand forecasts.


Commercially our product will be available from June 2017 as it is in production. Initial research and requirements were highlighted by Paula Tinniswood, Healthcare Transformation & Improvement Consultant who currently runs a Cancer & Clinical Support Division in a large Trust in London
Investment activity:
We would be delighted to receive support from regional trials in the West Midlands, should any of the NHS Trusts like to do a patient evaluation trial within their oncology departments.
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2017. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK. 


This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials. 
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Investment sought:
It would be very helpful to have further Health Economics support to capture the 'whole process savings' of using the Airglove system.


Our  trials and experience to date has demonstrated that the use of the Airglove system  improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.
Read more
Hide details
Sheena Jack 10/04/2017 - 13:29 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Radar supports health and social care organisations in holistically managing all aspects of their quality and compliance activity, whether intuitively building a CQC evidence portfolio or managing audit, incidents and risk.
Overview of Innovation:
Radar Healthcare system has been developed using the latest technologies and platforms to ensure a cutting edge and sustainable solution. The system adopts proven business rules in use across the health & social care sector in the UK and incorporates the Care Quality Commission (CQC) guidelines and procedures.
 
Radar Healthcare from Smartgate Solutions has been developed in partnership with knowledgeable and respected healthcare professionals. The system is scalable and configurable to organisational needs to meet both internal and regulatory requirements.

The Radar Healthcare modules help care providers meet their daily operational challenges and associated quality and compliance requirements. 
 
Radar supports organisations by: Taking the worry out of quality & compliance
  • A responsive system, allowing you to visualise and manage risk, training and regulatory compliance across the business domain.
Gain a clear line of sight into performance
  • Intuitive and dynamic dashboards providing real-time visibility of business performance at both location and organisational levels.


Automation of key procedures for operational efficiency
  • Translating business rules and SOP’s into action through our automated workflows and action tracking.
Reduce costs
  • Supporting a systems approach delivering demonstrable ROI across business resources, time and staffing.
 Radar Healthcare is currently in use across multiple service areas including Social Care, Primary Care, Specialist Clinics, Acute Care  and Patient Transport.
 
It’s primary purpose is to assist in ensuring each organisation meets relevant regulatory compliance standards and support organisations reduce duplication and effort in managing that process.
 
It will allow existing processes and procedures to be followed more efficiently and enable the introduction of new processes and procedures that are currently unfeasible with existing systems.
 
Key Facts
  • The system is made up of specific modules, each providing a range of functions that can support organisations in their daily operational activity.
  • All Modules work collaboratively and share data to avoid duplication.
  • Data can be integrated from various sources and other software system.
  • Dashboards and reports can be viewed and created by employees, by department, by directorate or as an entire organisation.
  • Each module has the ability to accommodate pre-configured workflows aligned to your existing SOPs, policies and procedures.
 www.smartgatesolutions.co.uk
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Radar Healthcare modules have been developed to help care providers meet their daily operational challenges and associated regulatory requirements. 
 
Adopting proven tool kits and processes, Radar Healthcare ensures compliance with the essential standards relating to the quality and safety of care as defined within the CQC and other regulatory bodies.
 
Cost Improvement (CIP) Opportunities
The CIP opportunities are variable and based upon the modules selected. Efficiency savings are realised through two specific means:
  1. Replacement of existing systems in use across the organisation
  2. Redeployment of posts supporting quality and compliance management and re-deploying skills to vacancies within the organisation
 
A high level simulation exercise exploring how the implementation of Radar could support the reduction of cost within an NHS Hospital in the North of England (approximately 3,500 staff serving a population of c250,000 people) identified potential savings of over £300,000 over a 3 year period.
 
Smartgate Solutions have developed a cost calculator capable of identifying cost against current systems and workforce requirements.
 
Efficiency Savings
Additional efficiency improvements can be realised through:
  • Ensuring compliance with CQUIN targets or other commissioning KPIs
  • Improved efficiency and productivity in managing quality and compliance activity
  • Smartgate can support organisations with their recruitment processes and reduce the time spent undertaking training post employment. Radar allows you to issue training and development content to employees prior to their engagement and for completion online, effectively tracking and monitoring their progress against the training content.
  • Reducing the time spend responding to requests from regulatory bodies and building evidence portfolios. Radar supports the on-going development of evidence portfolios, providing clear audit trails and concise reporting.
  • The system intuitively allows users and organisations to share information, allocate tasks and distribute vital information in real time. It provides a safe and effective way of sharing learning and information.
 Client Testimonial
“We are committed to delivering the highest levels of service and CQC compliance. Radar Healthcare has been the key factor in achieving and exceeding these goals.“
John Butterfield, CEO, ER Systems
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Radar supports providers and commissioners of health and care services to effectively manage and monitor their quality and compliance expectations, deliverables and regulatory requirements with greater efficiency and often with greater effectiveness.
 
Radar enables organisations to re-deploy their scarce resources to focus on the delivery of care, freeing clinical expertise from administrative activities. 
Current and planned activity: 
Current NHS Activity:
Radar is currently utilised by numerous providers of health and care services, many of which provide NHS services.
 
We are currently engaged in discussions with both CCGs and NHS Foundation Trusts.
 
At present we are exploring opportunities to grow our engagement with NHS organisations and are seeking support and guidance from colleagues at WMAHSN, Medilink WM and the wider regional health and social care communities.

Planned/required activity:
  • Procurement / Adoption of: -  Growth and increased adoption of Radar across NHS provider and commissioner organisations  
  • Partnership: We are interested in exploring partnership opportunities with NHS organisations that may help to realise a financial ROI
What is the intellectual property status of your innovation?:
All product IP is wholly owned by Smartgate Solutions Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Tom Lindley 30/03/2017 - 09:44 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
In healthcare settings, Splunk is a powerful, easy-to-use business intelligence tool that analyses real-time data from multiple sources — enabling managers to run more efficient healthcare services.
Overview of Innovation:
Unlike other business intelligence tools, Splunk is platform-agnostic and can address ‘ad hoc’, non pre-programmed questions. Converging Data Ltd provides secure, on-premise or a hybrid cloud solution that combines and analyses structured & unstructured data from multiple sources, including but not limited to HL7 data, even collecting data directly from internal data networks.
 
This data can be interpreted without the need for predefined schemas and structures, providing real-time performance monitoring across entire care pathway.
 
Converging Date Ltd has created specific healthcare applications utilising the Splunk software platform.

Splunk makes it simple to collect, analyse and maximise the value of big data generated by security systems and business applications and improve operational performance and results.

Healthcare Intelligence
Healthcare Services & Care Pathways can be visualised and analysed using the IT Health Intelligence solution & HIX (HL7 Health Intelligence Connector).
 
Gathering data from multiple sources, in different formats and without consistent standards is what Splunk does best. HIX takes HL7 data from PAS, Pathology, Pharmacy or Electronic Health Records and provide a clear picture of how care is being delivered in real time.


HIX allows organisations to easily collect HL7 data commonly transferred between clinical and administration systems.
 
The Care Pathway Profiling tool allows data to be represented in a form that can be mapped to local physical or logical care pathways.  Alerting options ensure that the right people are notified when thresholds in service levels are reached.
 
Patient Flow
This powerful, easy-to-use business intelligence tool analyses real-time data from multiple sources, enabling managers to run more efficient healthcare services. By gathering existing structured and unstructured data from across the organisation Splunk allows healthcare providers to view the entire care pathway and direct resources to address rapidly changing conditions.
 
The Patient Flow module can easily be tuned to match local care pathways and service delivery models. Advanced analytics can be used to track organisation’s KPIs and highlight anomalies & identify root causes.

The Patient Flow module uses the Healthcare Common Information Model (HCIM) that ensures data received from multiple systems can be mapped to HL7 standards and local nomenclature. HCIM allows searching and reporting across systems which are interdependent, but not interconnected.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Patient and medicines safety
Benefit to NHS:
The use of real-time data allows resources to be more efficiently deployed and problems to be more easily identified and addressed. Our ability to deploy across existing data sources means it’s fast to deploy and can demonstrate value within days.
 
We have worked with healthcare organisations to improve operational efficiency tracking patient flow, demographic breakdown of A&E arrivals, real-time location services within healthcare organisations. This allows more to be delivered with fewer resources and equipment and services to be tracked and located more quickly.
 
We have also provided detailed reporting and analysis of operating theatre utilisation and the actual costs associated with delivery of specific procedures. The real-time nature and alerting capability means that this is no longer a retrospective view, but an up to date view of what’s happening right now within a complex organisation.
 
Our Analytics Capability can also be used to address cyber security. The Splunk platform once deployed, delivers a powerful analytics driven Security Information and Event Management (SIEM) capability.
  • Splunk is installed within the NHS, and within one of the UK’s largest private hospitals.
  • Splunk is used to support NHS Digital services such as Spine and NHS Choices. 
  • Internationally we are working with Public healthcare organisations in Australia.
 NHS Choices: ‘By using Splunk Enterprise, NHS Choices has been able to improve the service it delivers to website users. The organization is now looking at new ways to deliver value from its website data, including helping the partner team track usage of content provided to over 600 syndication partners, and building product-specific dashboards for the product owners showing detailed performance and transaction status for key areas of the site’.

www.convergingdata.com
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Benefits from the deployment of this technology will be realised through better utilisation of resources and the ability to view the status of the organisation in real-time.
Current and planned activity: 
Current NHS Activity:
Rotherham NHS Trust (Pathology and Laboratory Data Services) - use Splunk to collect HL7 Data and provide visibility across Pathology and Laboratory activity.

NHS Digital: Splunk is used by NHS digital to support national IT infrastructures such as Spine and NHS Choices.

Planned/Required Activity: Planning Stage
Luton & Dunstable NHS FT  - NHS Patient Flow and Capacity Management System – to provide visibility across the patient care pathway. Splunk will be used to ‘pull’ data from clinical and administrative systems from across the Trust, including HL7 Data, creating dashboards, reports and alerts to show activity and highlight bottlenecks. Deployment initially with internal systems then rolled out to 3rd party organisations who provide care.

International:
  • Middlesex Hospital USA
  • Ongoing projects with Australian Department of Health and the Australian Digital Health Authority.
  • We are also supplying analytics capabilities into one of the UK’s largest private hospitals.
What is the intellectual property status of your innovation?:
IP protection is afforded by a mix of proprietary applications with Converging Data IP in some connectors and point applications.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Neil Murphy 29/03/2017 - 14:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ScanNav is a software package providing discrete, real-time support to sonographers during the FASP 20 week fetal anomaly ultrasound scan. ScanNav acts as a helpful peer review, an intelligent checklist ensuring complete, fit for purpose scans.
Overview of Innovation:
ScanNav® is a software package that provides support to sonographers during the 20 week fetal anomaly scan. It gives real time feedback to the screener on whether paused images are fit for purpose, and on whether the protocol has been followed. It is a peer review, a checklist with which the sonographer may disagree at any time.
  • Trained by human experts
  • Consistent
  • Objective
  • Always available
ScanNav:
  • Supports and assists in the supervision of newly qualified sonographers.
  • Provides oversight of locum sonographers.
  • Performs automated, prospective second trimester anomaly scan audit.
  • Provides real-time support for sonographers.
Newly qualified sonographers ideally need another sonographer in the room to assist with their scanning and with quality control, but peer review is time consuming, disruptive, subjective, and a more senior sonographer can’t be there 100% of the time.
 
ScanNav® automatically examines each image as soon as the sonographer presses pause.
It determines which (if any) FASP fetal anatomy view it represents. It then assesses fitness for purpose against the FASP criteria, reporting that opinion graphically, and giving the sonographer the option to disagree if they wish.
 
If the sonographer agrees, then no interaction is necessary.
 
If the sonographer choses to save the image, ScanNav® adds those criteria to the overall record of the view.
 
A separate interface allows managers to examine individual scans or aggregate performance against FASP criteria.  Over time, as the system observes many scans, statistics on scan completeness and quality are collated and can be presented as an audit report.
 
The sonographer always retains primacy. ScanNav® acts as a consistent colleague. ScanNav® always allows the sonographer to disagree with it.
 
www.intelligentultrasound.com
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption
Benefit to NHS:
ScanNav increases the efficiency of sonographers and managers in the 20-week FASP anomaly scan by
 
  • Supporting and assisting in the supervision of newly qualified sonographers.
  • Providing oversight of locum sonographers.
  • Performing automated, prospective second trimester anomaly scan audit.
  • Providing real-time support for sonographers.
 
Using ScanNav considerably reduces the effort required to provide comprehensive peer review and oversight of sonographers.

With ScanNav, the sonographer has immediate feedback on any paused image, identifying which criteria are present, and an automatic intelligent checklist that keeps track of progress through the scan. At the end of the scan, the user or their supervisor can see exactly what has been saved, and can comment, or take further action to complete the scan, as appropriate.

Supervisors can, at any time, easily see overall statistics on sonographer performance, enabling them to instantly examine any images where
 
  • The scan is not complete.
  • The sonographer has disagreed with ScanNav (ruling in or out criteria).
  • The sonographer has continued to save images where the view was already complete.

This can help guide training and support. ScanNav fits naturally into the standard workflow to enable time savings. Further efficiency savings are expected to be demonstrated once the initial software rollout start in mid-2017.

For managers, ScanNav® LFR enables automatic 100% audit of FASP 20 week views, something that is currently impractical.
 
Quality goal.

It is also hoped that ScanNav will improve outcomes. A retrospective audit at one NHS trust showed that nearly 50% of scans had at least one missing view. There are many reasons why this might legitimately be the case – e.g. high maternal BMI or unhelpful fetal position, but ScanNav helps to ensure that any views missed are done so explicitly, with reasons for the missing view recorded. This has both quality and medico-legal benefits, allowing compliance with protocol and due diligence to be easily and reliably demonstrated.
Initial Review Rating
3.67 (3 ratings)
Benefit to WM population:
It is well known there is a continued shortage of sonographers. With recruitment being difficult, training and retaining sonographers to reduce reliance on agency workers is the ideal solution, but this inevitably increases pressure on experienced sonographers.

Experienced staff invest a lot of effort and time when training and supporting newly qualified sonographers. Likewise, locum sonographers may require significant supervision from experienced members of the team - adding to an ever-increasing workload. ScanNav will considerably reduce the time needed to provide this support, increasing capacity and reducing costs.

It is also hoped that ScanNav® will improve outcomes. A retrospective audit at one NHS trust showed that nearly 50% of scans had at least one missing view. There are many reasons why this might legitimately be the case – e.g. high maternal BMI or unhelpful fetal position. ScanNav helps to ensure that any views missed are done so explicitly. The live automatic checklist makes it easy to see if any views are still outstanding, and the software will prompt the sonographer to easily record the reason for any missing views at the end of the scan, eliminating accidentally missed views.
Current and planned activity: 
ScanNav has been trained using a team of experienced NHS sonographers and over 370,000 ultrasound images, and tested with 60 professionals across 31 clinical and governance institutions, A prototype has been used at the John Radcliffe in Oxford. A demonstration of the software has been shown to two UK trusts so far, and the sonographers preferred ScanNav to manual peer review.

This demonstration of the software is now available to potential Limited First Release (LFR) partners. We want sites to use the CE marked beta software free of charge to assess utility and report back as part of a post market surveillance exercise.

We would like to work with sites to assess how the software enables them to change practice. As a part of this, we would perform an anonymous analysis of one year’s prior images saved under FASP. A full analysis of the completeness and fitness for purpose would be undertaken, allowing a direct comparison of performance before and after the introduction of ScanNav LFR.
What is the intellectual property status of your innovation?:
IP held by company. Simulator is not applicable to patients. LFR release will hold a medical CE mark.
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Gordon McKenzie 27/03/2017 - 07:22 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
doDOC streamlines collaboration by bringing people and processes together into a single platform, with end-to-end auditability, saving up to 70% in documentation time.
Overview of Innovation:
Life Science and Academic organizations operate in an extremely document-intensive, highly regulated environment. doDOC support this critical process of producing collaborative, compliant, quality documents within tight deadlines.
Whether working with a few individuals or large geographically diverse teams, doDOC makes the co-authoring, review and approval process less painful and more efficient by ensuring neither document quality nor deadlines are compromised in a integrated platform solution.
 
Documentation processes are typically managed in silos by multiple software in each working group of individuals leading to errors, duplicated information and delays, wasting billions of working hours every year.
 
doDOC proposal is simple: a single collaborative platform for the creation of documents with granular control over information processes and a system capable of integrating information from multiple sources avoiding duplication and manual tasks, generating a comprehensive audit trail with measurable effectiveness.


 
How doDOC does that?
1 – Streamlining collaboration and avoiding typical project miscommunication problems;
2 – Automating workflows, ensuring that the right people is doing the right thing in the right moment;
3 – Changing the writing process from a step by step reality to a concurrent and symbiotic experience;
4 – Bringing automation to technical tasks related with document production that until now undermine productivity;
5 – And since doDOC tracks every single event over the entire project, doDOC provides unique insights to allow managers and team members to track progress and access performance in real-time.
 
This change in the technology behind the creation of information allows doDOC users to decrease immensely the total time for the execution of their document-based projects.
 
doDOC Features:
Absolute Security: Full confidentiality, integrity, availability and auditability;
Real-time Collaboration: Collaborate in real-time across departments, regions and organizations.
Automatic Formatting: Full focus on content and automated publishing;
Full Control: Notifications, roles and accesses controlled automatically;
Information Integration: Centralize all records and information in one place;
Custom Workflows: Drive processes automatically and improve efficiency;
Simple Project Management: Optimize virtual teams and operations;
100% Traceability: Provide real-time insight with activity dashboards.

More about doDOC Platform: doDOC Product
More about doDOC: Website
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
doDOC is a proven cost effective solution for the document co-authoring, review and approval process, providing an excellent return on investment (20X ROI) with both tangible and intangible benefits.
 
Key benefits to NHS by the use of doDOC is the streamlining of cooperation among healthcare professionals with impact on the following areas: patients, processes and knowledge.
 
Improved Patient Care: The complexity of managing patients’ health records requires a cooperative effort that encompasses all of the healthcare professionals involved in their care, each in his/her area of expertise, in order to achieve the best outcomes. doDOC streamlines report generation, focus on the content and decrease the time spent in administrative tasks.
 
Better Process Efficiency: Another variable mentioned when analyzing the usefulness of working together was improving the process. By employing doDOC, the organization is automating the application of standard operational procedures and ensuring compliance with best practices. This improvement in the processes leads to greater efficiency and to an increase in the quality of the healthcare given to the patients.
 
Promoting Knowledge: The importance of collaborative work was also noted for facilitating knowledge among professionals, optimizing time and resources. doDOC allows sharing information in a more effective manner. By controlling information across the network, professionals provide knowledge that is securely shared, with improved health being the result.
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
doDOC will promote greater collaboration between the West Midlands Health Organizations: Universities / Hospitals / Companies have with doDOC a single collaborative and secure platform to create value and generate positive impact for the local population.
Current and planned activity: 
doDOC currently works with Top10 Pharmaceutical Companies and world-leading research organizations.
doDOC aims to streamline collaboration across life science and healthcare institutions by simplifying the collaborative effort within document-based projects.
What is the intellectual property status of your innovation?:
Registered Trademark
Trade Secret
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Carlos Boto 17/03/2017 - 16:33 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Accounts payable staffs spend up to 30% of their time responding to supplier queries. Solv.ai’s first product resolvr™ solves the problem at 10% the cost. Resolvr™ is cloud-based messaging applicationsupplier specific responses on behalf of AP teams 
Overview of Innovation:
According to the Procure to Pay Network, accounts payable departments spend up to 30% of their time responding to supplier queries. Solv.ai’s first product resolvr™ solves the problem at 10% the cost.  Resolvr™ is cloud-based messaging application that provides speedy, supplier specific responses on behalf of accounts payable teams.  We use any channel such as email, browsers like Firefox, Edge, Chrome, and any messaging application such as skype, slack, facebook, etc., so suppliers don’t have to download a new application, or sign into a new portal to use our service. 

Solv.ai aims to leverage the latest artificial intelligence technologies and apply them to business to business communication.  At solv.ai, we understand the importance of aiming high but taking sensible, practicable steps to build a launching pad for our ultimate goals.

Our first products are resolvr™ and resolvr:email™. They represent the first natural language process applications specifically designed to automate responses to suppliers on behalf of accounts payable departments. The total addressable market for resolvr™ and resolvr:email™ includes all businesses with suppliers and an accounts payable function.  This is most global B2B activity. 

The founding team are experienced procure-to-pay, e-invoicing, and digital cash experts.  We have broad and deep contacts in the industry and plan to use all of them to make Solv.ai succeed.  

The founders are very confident in the success of resolvr™, as a standalone application that competitors may emulate over time, but more importantly cross selling opporutnities for buyers to sell into suppliers can facilitate tremendous benefits between buyers and suppliers. 

Solv.ai has a co-innovation agreement with Birmingham City Universty's Centre for Cognitive Digital Systems Engineering to build out a suite of APIs as a platform for other supply chain interaction efficiencies.  This would include integration and interoperability, and enhance logistics and procurement activities. 

The immediate benefit resolvr and resolvr email can offer the NHS is reduced costs, but over time, solv.ai can help transform the trade transaction life-cycle by implementing an "AI-first" approach to procure to pay.  The NHS could be the first to employ an AI-powered communication layer that supports supplier information management, file tranformation, integration, meta-data for its communication activities with its supplier base. 





 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health
Benefit to NHS:
  • Up to 80% reduction in supplier queries
  • Enhanced Supplier experience; 24/7 access, immediate responses
  • Real-time, multi-channel communication with supplier base
  • Gain insight and improve external communications with reporting and analysis
  • Achieve P2P streamlining promised by existing solutions
  • Partnership approach when drafting SLA
Initial Review Rating
2.60 (2 ratings)
Benefit to WM population:
More efficient public sector activities.
Current and planned activity: 
We are not currently engaged with the NHS.
What is the intellectual property status of your innovation?:
Our technology is proprietary and we have trademarks for our company name and product name.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 17/03/2017 - 11:29 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
SEEING WHAT OTHERS SEE, AND WHAT THEY EXPERIENCE IN THE PROCESS
Eye Control, Eye Perception, Eye Emotion
Affordable,Intelligent Digital Eyewear
Overview of Innovation:
Eye Hyper Tracking System - Smart Wearable
Viewpointsystem has developed a completely new system to measure and understand human perception through the eyes.
The Eye Hyper Tracking doesn't just capture the line of sight,but also how the person reacts to what is seen. The system in the form of smart lightweight safety rated glasses allows extremely precise measuring of observations and insights coupled with the ability to SHARE what is being seen via REMOTE LIVE STREAMING.
  • Telemedicine - A health professional can conduct or instruct a procedure with the aid of a precise hands free view.
  • Training - Any aspect of training can be covered, be it a live event or with the ability to record 'what is seen' it can be then shared, learned from and shown as a unique prespective into the instructor or wearers' viewpoint and preception
  • Paramedic / 1st Responder - Imagine a world where an expert can see what you are looking at and give you on the spot support. Envisage a paramedic or 1st responder calling in advance to show the recieving hospital the extent or seriousness of a situation
  • Improving Results - Instructions are often given and confirmed as being understood, communication is key in getting things right first time. With a view of 'how' to carry out a instruction, in certain circumstances a person viewing your first attempt is both supportive and safe.
  • Reducing Costs - Specialists cannot be everywhere all of the time. With a live streaming function, they are only ever a click away to see what you see, thus reducing the need to travel, rebook appointments, move from place to place.
The system has truely endless possibilites. Having been in the scientific arena for a number of years it is proven to be relaible and very accurate. Our system takes the technology from the lab into the real world, being light, highly mobile and robust it is user friendly, simple and smart.

The revolution in the measurement and interpretation of human perception has truly begun.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
NHS Benefits
  • Efficiency - Simulation of scenarios for training
  • Efficiency - Centrally situated teams all viewing the same situation though the same perspective
  • Efficiency - 1st Responder / Paramedic support given, time saved when arrival at hospital, faster turnaround times
  • Efficiency - Right 1st time approach to training, supportive and inclusive
  • Efficiency - Faster turnaround times for paramedics at hospitals
  • Cost Benefit - Travel of key staff and personnel
  • Cost Benefit - Training budgets reduced to all areas
  • Cost Benefit - Specialists can support remotely, no need to always attend sites
  • Cost Benefit - Abilty to simulate a scenario or situation. Feedback could be given by instructor remotely
  • Cost Benefit - General hospital infastructure - The system is applicable to services outside of medical arena - IT support, Machinery supplier support, building support.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The system is designed to support all industries with medical being a specific area.
Our system not only enables faster, safer, most cost efficent ways of doing things, it provides an enabler to reduce time and improve effectivness.
Any improvements or cost savings can only help improve patient or colleagues healthcare, reduce waiting lists and improve services. It is also key to ensure the highly trained dedicated staff have every possible piece of equipment to help improve their working life balance and conditions.
Current and planned activity: 
Our current status is to engage with all 15 AHSN's in the UK.
Our system was only launched in UK in Sept 2016, and we have only just started to engage with the UK health sector.
We have a number of doctors, paramedics and hospitals trialing our system in Europe, and we have just engaged with a leading surgeon in USA who is keen to try our technology, as he was the first surgeon to use Google Glasses to carry out a live stream procedure.

Our primary intention is to be seen and heard by the NHS. We are keen to visit and demonstrate the system and possibilites first hand, as we are not a concept as we have an actual fully functioning system ready to use.
What is the intellectual property status of your innovation?:
We have IP on certain elements of the system.
Eye tracking is commonly adopted in VR/AR system is various guises.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Graham German 23/02/2017 - 11:14 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Aptvision is revolutionary to the radiology sector providing a paperless & cost effective workflow.  Designed with radiology experts, practiced in-depth and customised to meet the specific needs of today’s modern & demanding radiology environment.
Overview of Innovation:
Total Radiology Solution including RIS and other innovative solutions has been designed to increase efficiency in hospitals and clinics - not just to store patients’ data. It’s unique innovation can be seen in:
  • Cost savings and increased productivity
  • Increase revenues for hospitals and clinics: web booking, schedule optimisation
  • Reduce errors and staff duties
 
Aptvision RIS is the most innovative RIS on the market offering fully paperless workflow from start to finish: eReferral letters automatically attached to the RIS, e-consent forms, Online Results, etc. Aptvision RIS also assures:
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • Fully web based, no installation - just the web browser
  • Ability to report on studies from any location without a need of installing dedicated software on individual doctor’s PC.
 
Much more than a standard RIS, Total Radiology Solution offers:
  • Fully integrated Web Booking in which patients can book their appointment like a seat on an airplane. From the clinic’s website patients can see which appointments are available for the type of exam they need and book it immediately.
  • Aptvision’s system automatically provides a call back from a clinic’s Call Centre, to verify the selected appointment and go through safety questions. The operator is prompted by the system to ask the appropriate questions.
  • This feature has reduced the 40% dropped calls rate to zero and practically eradicated no shows and errors.
  • Before the appointment, the patient receives a SMS Reminder of their visit and gains access to the Online Consent Form. They can complete it on their phone or computer before their visit day.
  • On the appointment day, patients can use Online Registration in the clinic using the interactive kiosk or tablet & without the need to stand in a long queue at the reception. They can also monitor their live updated waiting time on dedicated monitors.
  • The electronic consent form as well as all previous medical history is attached to patient’s record in Total Radiology System leading to completely Paperless Workflow. Once the appointment is completed, patient is informed with an SMS telling them their results are ready and can be viewed in the Online Results portal if this is appropriate.
  • Voice Recognition to more quickly create medical reports
  • Scan Audits to improve the quality of the reports and enable sharing of expertise.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Revenues increase
  • Across 16 clinics in Ireland we have facilitated savings of up to €600,000 per clinic through reducing no-shows, errors and through modality optimisation
  • We have also increased revenues by €2.4 million in an 18-month period through web-booking and e-referrals
 
Efficiency increase and cost reduction
Through fully paperless workflow
  • An advanced, configurable, fully integrated e-referral platform feeding actual availability of modalities
  • E-referral letters automatically attached to the RIS, e-consent forms, Online Results, etc
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • ensure scan is possible and safe for patient (availability & safety questions)
Reduction of manual processes
  • Fully business rules driven without manual intervention
  • Built-in processes for auto scheduling and bulk appointment operations
  • No re-typing of information
  • No web booking missed
  • Medical call centre takes over all calls so reception could focus on patients and their needs
  • Interactive kiosks, tablets and monitors allow patients to register online without a need to come to reception
Improved Patient satisfaction
  • Reduced waiting times for scans and results
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
 
Quality improvement
Peer review feature that allows anonymous review of radiology reports by random peer
 
Better hospital/clinic management
Live updated personalized dashboards for quicker decision making and detailed reporting: revenue reports, comprehensive operations reports, etc.
 
Savings in time
  • Quick system implementation - within few days, not months
  • Easy and intuitive up and running in 30 mins
  • Improvements visible from day one
 
Existing customers have reported statistics of:
  • Modalities capacity increase of 30%
  • 1 extra scan per hour
  • 10 more booking per day
  • Reduced reporting time 20min -> 4min
  • 50 reports per day vs 15
"Aptvision is revolutionary to the radiology sector and is the key to a paperless workflow. It improves daily operations and leads to quicker reporting times and early diagnosis. My experience suggests that Aptvision RIS increases a clinic's efficiency and bottom line from day one and has been the answer to our digital problem in one step."

Prof. Michael Maher
Consultant Radiologist, Cork University Hospital
Professor of Radiology, University College Cork
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
With rapidly increasing demand for diagnostic imaging and hospital and clinics workflow heavily relying on paper and manual duties radiology providers are sometimes unable to cope with that increased demand and provide their diagnostic in efficient and timely manner which can result in patient dissatisfaction and in some cases even lost lives.

Aptvision Total Radiology Solution offers a solution that can revolutionize radiology industry by promoting efficiency and paperless workflow that increases productivity in hospitals and clinic and ultimately benefits patients and their lives.
Our innovative features can benefit patients in numerous manner including:
  • Better and quicker access to radiology
     
  • Reduced waiting times for scans and results which can save lives
     
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
     
  • Quality improvement - Peer review feature that allows anonymous review of radiology reports by random peer. It improves the quality of the reports, enhances share of expertise and allows discussion of interesting cases with experts in anonymous manner. This hugely benefits patients and again helps to save lives
     
  • Make use of modern ecommerce technologies to patients
Current and planned activity: 
Aptvision has just completed the Serendip programme.

We have applied for late inclusion into supplychain RIS/PACS frameworks.

We are actively engaging with Queen's hospital (BHR hospitals trust). We have presented the system and received a very positive response and we are currently organising a full day workshop with all staff.

We are presenting shortly to Black County Alliance.

We are seeking to work in partnership with an NHS Trust to deliver an early demonstrator for the NHS.
What is the intellectual property status of your innovation?:
Full intellectual property of all applications and solutions is owned by Aptvision Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Fiona Smith 14/02/2017 - 10:23 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Replace paper forms with digital forms, and integrate with time/material/asset mgmt. system.
Overview of Innovation:
Summary marketing video : https://www.youtube.com/watch?v=Li-zNgGm6FE

Boost Productivity, Workplace Safety and Reliability with "myJobCard". 

“myJobCard” is a mobile Work and Asset Management application which integrates with SAP ERP and come with an inbuilt dynamic form engine.
“myJobCard” brings together best practice from our extensive experience of deploying Mobile Asset Management solutions, incorporates feedback provided by our customers, and leverages latest advancements in mobile technology.
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Innovation and adoption
Benefit to NHS:
Increased Productivity
1. Save time needed to convert paper forms to electronic forms.
2. Sending jobs directly to staff and get updates in real time in backend system on job updates.
3. Show history of asset repairs to avoid repeated issues.
Reduce cost
1. Better management of materials required to carry out certain jobs
2. Cost savings from increased productivity
3. Cost savings by reducing IT involvement in form creation process.
Better analytics
1. Optimise working time against the waste through better analytics based on real time and accurate capture of information
2. Better decision making based on accurate and better capture of information.
Initial Review Rating
1.80 (1 ratings)
Benefit to WM population:
1. Cost savings of NHS service to public and nation as a whole
2. Assets uptime increased
3. No need to provide information time and again to fil forms. some information auto-populated.
Current and planned activity: 
myJobCard has been launched recently in the market and we are looking for pilots/PoC customers.
What is the intellectual property status of your innovation?:
There isn't any IP in the app which can be protected. App is protected through copyright.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Innovation is global in nature and is scalable.
Measures:
1. Improved productivity
2. Imprved Data Quality
3. Improved Health and Safety
Adoption target:
Target for WM are 2-3 customers by end of year.
Globally we are looking at 10-15 customers in first year.
Read more
Hide details
Navdeep Singla 02/02/2017 - 12:02 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Optimised Equivalent® to best performing & highest volume branded orthopaedic implants (>1,000,000 patients), coupled with significant savings. Equivalent manufacture, materials, tolerances & sizes, along with operational technique & instrumentation.
Overview of Innovation:
The UK is the first country in the world to benefit from applying the principle of generics to orthopaedic products. Generic medicines have been a core part of the NHS since the 1980s, offering the same clinical outcomes for patients as originator drugs and now contributing over £12 billion in savings every year that can be reinvested into the health service (1)

With >66,000 NHS hip replacement operations performed every year (2) switching to generic hip implants from the current market leaders, the NHS could save up to £120 million by 2020 - enough to fund over 1,400 junior nurses every year (2,3,4)

This is well-timed following Lord Carter’s Review, which found that large efficiency savings can be made by all NHS hospitals – notably in orthopaedics. Some of these savings can be made by reducing the current variation in patient outcomes (5)
 
Evidence from over 1,000,000 hip replacement operations in published registry data shows that some of the most widely used devices with the lowest possible revision rates can be provided at a significantly reduced cost due to patent expiration. Orthimo have produced Optimised Equivalent® implants to the branded versions, providing significant cost savings without compromising patient outcomes.

The manufacturing of the Optimised Equivalent® implants are by well established suppliers with many decades of experience in manufacturing orthopaedic implants for the large Orthopaedic companies, further strengthening the equivalence value proposition.  Both the surgical instruments and techniques are also equivalent.

As a further indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent® implants through a forward buying fund, which can be obtained via NHS Supply Chain.
 
At a time of unprecedented cost pressures on Healthcare systems worldwide, Optimised Equivalent® implants make a valuable contribution towards maintaining high quality hip replacement services within the limited resources available.

This means patients receive the best clinical outcomes at significant cost savings for hospitals.

http://www.odep.org.uk/Product.aspx?pid=2301

http://www.beyondcompliance.org.uk/product.aspx?pid=2301

https://my.supplychain.nhs.uk/Catalogue/product/fjh10279

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence
Benefit to NHS:
Orthimo provide equivalents of the best performing and most commonly used branded orthopaedic implants, as proven by registry data of over 1,000,000 patients. Similarly to generic pharmaceuticals, which the NHS already takes advantage of, Orthimo products come with significant savings of 30-60%. This could save the NHS up to £120million by 2020.
 
These can be provided with minimal disruption to services and procedures due to the sizes, instrumentation and operative technique being equivalent to the most commonly used branded products. They are available through a simple and transparent pricing structure, which can be via the Total Orthopaedic Solutions, Chester or NHS Supply Chain frameworks.
 
As an indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent ® implants through a forward buying fund, which can be obtained via NHS Supply Chain. With most Trusts using one or more of the branded reference components, a transition to make savings has never been easier.
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
Orthimo provides generic versions of the best performing hip implants, this means patients in the West Midland area can receive the best clinical outcomes at significant savings to the hospital and trusts in the region. 
 
In the West Midland approximately 6,000 hip replacements are performed per annum. If, at a conservative estimation, these cost £700 each on average, generic hip implants could save the West Midland area over £1.5m per annum.
Current and planned activity: 
With Optimised Equivalents being available via all Orthopaedic frameworks, Orthimo are seeking Surgeons to conduct small volume evaluations or for Trusts to allocate a proportion of their hip work.

As with the generic pharmaceutical industry, there is a need to establish a policy change to ensure the responsible and active use of generic orthopaedic implants.
  • Procurement: -  Require sales and marketing to Trauma & Orthopaedics departments and procurement
  • Evaluation - Seek ‘Beyond Compliance’ service evaluation centres for uncemented range
  • Adoption:- Seek Hospitals/Surgeons to conduct small volumes of procedures
  • New Product Development:- Require experts to propose and support development of new products
What is the intellectual property status of your innovation?:
All IP resides with Orthimo.

Orthimo holds BSI CE Mark for all implants.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Optimised Equivalents use the most common and best performing branded reference products. These are used in most Trusts across the country, and so an introduction will have minimal disruption. We use the same sub-contracted manufacturers and logistics which the large companies use, and so supply can be scaled rapidly. 
Measures:
Our products are being used via the Beyond Compliance process. This data will be used to apply for successive ODEP ratings when the criteria are acheived. 
Adoption target:
We are looking for Trusts to use Optimised Equivalents for their low risk, common primary elective total hip replacement procedures. It has been estimated that this would be in excess of 60% of cases. 
Read more
Hide details
Oliver Wylie 09/01/2017 - 15:16 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Incredible amounts of expensive drugs are thrown away by pharmaceuticals companies, health trusts & GP surgeries due to refrigeration problems. Everyware technology enables remote data monitoring & intervention for pharmaceutical & food storage
Overview of Innovation:
The problem. Correct handling and storage of drugs and medicines is critical in ensuring that they remain functional and safe to use. Regular monitoring and data capture highlights trends and issues not evident from manual record keeping. Over weekends and during holiday periods readings may not be recorded. Failure of a refrigerator or break in power supply could render contents unusable or remain undetected
 
EveryWare has developed an intelligent software platform with smart sensors, integrated and modular, in conjunction with clinicians to tackle this major problem. Local devices monitor a range of parameters, including ambient temperature, pressure and humidity; together with refrigeration temperatures at different levels within each unit
 
Local and remote alerts can be triggered when your own defined rules are breached. Alerts may be visual and audible in a monitored location with users receiving direct notifications via email, SMS and other channels. Data is visualized and accessible on computers, tablets and smartphones
 
Testimonial
Clinical bodies and Trusts’ guidelines require regular monitoring of critical storage temperatures. Legislation requires that records are kept and this is often a manual task with readings taken at up to 24 hour intervals
 
Successful trials yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7

Differences between types of refrigerator become evident. Recovery time following prolonged periods of access can expose the contents to raised temperatures for longer; trend data clearly demonstrates the effects of daily routines and identifies opportunities for training that will improve the safe storage and dispensing of critical medicines
 
EveryWare’s unique modular system means that the unit cost of the sensors is low. All other costs are capped, so no need to worry about data rates and variable costs. Annual cost of the system is a fraction of the cost of the assets or processes being monitored. System is designed from the ground up to be completely user-configurable to suit local and business requirements. Security is paramount; all cloud systems and data are network-isolated, multiple-passkey protected with encrypted communications.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Compliant drug storage
There is a legislative requirement to store critical medicines within specified parameters. Moreover, it is imperative that safe storage can be demonstrated and that only safe products are used.
 
Equally, any fault or disruption to the storage infrastructure doesn’t automatically render the products beyond safe use. Smart monitoring, reporting and validation afford peace of mind. Efficacy of the drugs can be evidenced and detect abnormal patterns of behaviour or access issues e.g. refrigerator door left open.
 
Broad clinical guidelines indicate that regular, period monitoring by technicians will suffice; often once every 24 hours and often not during weekends and holiday periods.
 
There are several risks with this approach that can render expensive drugs ineffective and worse still, fail to deliver the anticipated results. A power outage in the early hours or over a weekend may be masked by a reinstatement long before working hours. The damage may already be done if excessive temperatures have been realised.
 
The solution is to introduce smart monitoring with remote data logging and alerts. Continuous, electronic monitoring not only captures specific events 24/7 and raise alarms but provides valuable trend data. Battery backup will buffer mains failure without disruption to the monitoring or connectivity. Real time monitoring has clearly shown systematic issues occur out of working hours and variations within specific refrigerated facilities. Clinical practices will also affect the storage conditions; a feature that is evident from trend data. The effects of prolonged loading and unloading with the refrigerator open shows the impact upon refrigeration temperatures and the extended recovery time to achieve safe storage temperatures when eventually closed. Access to the refrigerators out of prescribed hours may also raise an alert if there is a security concern.
 
EveryWare has installed local monitoring systems in hospitals and clinical environments that are capable of tracking a range of critical conditions. Not just in refrigeration units but ambient conditions in key locations may be monitored through a common network. Within treatment, theatre, storage or living areas the network of wireless devices can track temperature, relative humidity and pressure along with other factors such as controlled access and refrigeration performance.
 
In homes EveryWare could be used with ambient and movement sensors to detect risk of hypothermia or falls.
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Overall benefits summary
Installations of the system have already demonstrated potential savings in recent trials.
  • Money saved by GP surgeries and health trusts through proper refrigeration of medicines
  • Money saved by pharmaceuticals companies through proper refrigeration 
  • Money saved by pharmaceuticals companies by not having to pre-emptively over-produce product to compensate for GP and trust wastage
  • Quality of patient care increases as a result of cost savings throughout the medicine supply chain
  • Meets strict legislative requirements ((strict environmental monitoring protocols are now required by CQC. Failure to comply requires drugs be destroyed at very high cost).
  • Modular (easy to add on additional ambient sensors, movements detectors etc)
  • Quick to install and upgrade
  • Predictive analytics software enables custom ‘rules based’ alerts to be created easily
  • Monitor multiple installations and multiple sensors from a single location (Dashboard)
     
Quality control
  • Constant monitoring of refrigeration and the ability to react instantly minimises the amount of wastage caused by medicine being spoiled by high temperatures. The unique modular design enables additional sensors to be quickly integrated. Predictive analytics software enables custom ‘rules based’ alerts and monitoring protocols to be easily created and monitored.
Legislation
  • The easy monitoring of temperatures makes it much easier to comply with the strict legislation imposed by health bodies such as the MHRA and CQC.
     
GP Surgeries
  • Surgeries and trusts are able to monitor the temperature of their drugs in the refrigerator and react instantly should parameters be broken.
     
Patient care
  • The cost savings made by reducing wastage can be channelled back into the healthcare system, improving overall patient care.
For more information see: http://www.everyware.uk.com/products/21st-century-drug-monitoring
Current and planned activity: 
Current Activity
Successful trials have been conducted with SWFT Clinical Services Ltd (a subsidiary of the South Warwickshire NHS Foundation Trust) which yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them.
 
Positive actions were taken to improve the effectiveness and avoid potential problems that might have occurred. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7.
 
We have recently entered discussions with GP practice in Norfolk in response to CQC’s strict environmental monitoring requirement for drug storage.

Planned Activity
  • We would welcome NHS input in our systems design and further development
  • We wish to increase awareness within GP and CCGs
  • We are seeking additional trial sites
What is the intellectual property status of your innovation?:
All IP resides with the company
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Nigel Maris 18/10/2016 - 08:42 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Tipsim® is a completely new product producing long lasting improvements in sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma or other neuro diseases e.g. Complex Regional Pain Syndrome.
Overview of Innovation:
Tip-stimulation with Tipstim® facilitates long-lasting therapy procedures. By sensory stimulation of the finger tips, Tipstim® drives plasticity processes in cerebral areas involved in the activation of the hand and fingers. Specially designed stimulation patterns – developed over many years of research & trials at the Institute for Neuroinformatics at the Ruhr University Bochum – are generated by a small, portable electronic pulse generator and applied directly to the finger tips via a completely new and highly-sophisticated therapy glove. The Tipstim glove® is the first product of its kind to utilise a new advanced medically approved conductive and biocompatible textile.
 
The therapy is completely painless, without side-effects and very easy to apply. The patient simply pulls over the glove, connects it to the pulse generator and starts the therapy session once a day for 1 hour. The therapy does not demand any special attention from the patient. Due to the small size of the pulse generator, the therapy can easily be integrated into everyday life and home. In principle, therapy can be applied everywhere, even when out walking.


 The proven efficiency of Tipstim® results from stimulation pattern specially designed for most effective enforcement of neuroplasticity processes. Clinical studies show that these special patterns produce cerebral changes which lead to persistent improvement of a patient’s sensorimotor abilities. This especially true with sensory and proprioceptive deficits which have shown a greater recovery than with standard rehabilitation therapy alone
 
Studies have shown that sensory stimulation drives plastic processes in the brain areas activated by the stimulation. This induces reorganisation in and around those brain areas that became dysfunctional by stroke or other brain injuries. This reorganization facilitates reactivation of cortical tissue that has preserved some functionality. The resulting remodelling of cortical circuits then mediates functional recovery.
 
Tipstim® is a clinically tested and CE approved product. The efficacy & safety of Tipstim® therapy has been proven in rigorous clinical trials.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
Stroke is the UK’s third biggest killer.
 
First-time incidence of stroke occurs almost 17 million times a year worldwide; one every two seconds. Stroke is one of the largest causes of disability – half of all stroke survivors have a disability.
 
In the UK there are 152,000 recorded incidences of stroke a year and currently over 1.2 million stroke survivors. The economic costs of stroke in the UK from a societal perspective totals around £9 billion a year (Source: State of the Nation Stroke statistics - January 2016). The average cost of care (acute & rehabilitation) per stroke patient is currently £23,315 (National Audit Office. Progress in improving stroke care..., (February 2010). NAO Report (HC 291 2009-2010))
 
Over a third of stroke survivors in the UK are dependent on others.
 
Tipstim® is a completely new product to improve sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma and other neurological diseases such as Complex Regional Pain Syndrome.
 
Tipstim® comprises a small, battery powered electronic pulse generator unit and a close fitting glove that delivers the neurostimulation at the finger tips. Due to the compact size of the pulse generator, the therapy can easily be integrated into everyday life. In principle, therapy can be delivered everywhere, even during walking or when reading or watching television.
 
Clinical trials have demonstrated that the stimulation provided by Tipstim®  demonstrates a persistant reactivation of affected brain areas responsible to sensory and motor control of the hand and fingers. Moreover, balancing processes in adjacent non-affected brain areas are promoted.
The result is a substantially improved sense of touch as well as an improved mobility of the concerned hand.
 
The sensory & functional improvements resulting from Tipstim® neurostimulation have been demonstrated to last longer than for traditional therapy alone.
 
The Tipstim® is self contained and can easily be used by the patient in their own home. This reduces the frequency of hospital / clinic visits, frees up therapist time and would enable more patients to be treated than is currently possible.
 
Furthermore, the sensory and functional improvements resulting from the Tipstim® therapy will increase the patient’s ability to carry out task of daily living and will therefore increase their independence, thus reducing the need for additional care and support – with resultant manpower and monetary savings.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands has the highest mortality for stroke in England in people over 65.
 
The region’s ethnic diversity and socioeconomic status also reflects in a higher than average incidence of strokes as people of black and South Asian origin are at double the risk of stroke as are those living in the most economically deprived areas of the UK (West Midlands has 28.1% of its population in the most deprived national quintile)
 
These statistics demonstrate that the demand for stroke rehabilitation services will be higher than the national average and therefore the opportunity to make a significant impact will be greater for therapies such as Tipstim®.
 
The region also has the lowest percentage of patients returning to their usual place of residence, and this is statistically significantly lower than the England average. Improved  independence and post stroke rehabilitation would help to address this and enable people to return to their own homes and live independently.
Current and planned activity: 
We are currently undertaking a pilot multicentre clinical trial of Tipstim® at the Countess of Chester NHS Foundation Trust, Chester.
We would welcome the opportunity to engage with the West Midland’s Stroke rehabilitation communities to raise awareness of our Tipstim®.
In addition, we wish to explore support for business model development and delivery strategies for NHS adoption and or private procurement.

We are also very interested in conducting a cost benefits analysis health economics study of therapeutic intervention with Tipstim®.
What is the intellectual property status of your innovation?:
Tipstim® is protected via granted patents and registered design rights held by the parent company.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Bharat Vadukul 21/09/2016 - 12:15 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Flo-Tone CR is a tool helping patients acquire good Maintenance & Technique in using Pressurised Inhalers, teaching how to Inhale SLOWLY and STEADILY. Inhaler Technique Skills are important and a major theme in BTS, GINA and NICE guidance.
Overview of Innovation:
Flo-Tone MDI (also known as Flo-Tone CR) uses a ‘Positive’ Coaching Whistle to help patients learn to inhale SLOWLY and STEADILY. Whistle Signal is a prompt for the canister to be pressed releasing the medication & the duration of the Whistle helps the professional to coach the patient towards correct use.
Pressurised inhaler mouthpieces come in a variety of shapes, accordingly Flo-Tone was originally produced in ‘Circular’ & ‘Regular’ Models. A new improved Flo-Tone CR now fits all mouthpiece shapes by fitting inside the pMDI mouthpiece. The new design ensures all pMDIs produce a whistle at the same flow rate, helping standardise technique.
Studies have been conducted with the new Flo-Tone to ensure that it delivers the full dose. The first study detailing the development of the improvement & its performance was presented at BTS 2015 & subsequently at DDL26.
Available on prescription, the improved Flo-Tone CR can be used with a pMDI simulator (Trainhaler) for training & with the Patient pMDI. It incorporates a cap so that it can be left in situ on the Inhaler. It also includes a rim on the mouthpiece to help patients get their teeth out of the way of the aerosol spray.
We have tested Flo-Tone CR with a variety of inhaled medications (Flutiform, Clenil, Ventolin, QVAR and Sirdupla) – in each case the respirable dose (ie that part that reaches the lungs) delivered for the medication plus Flo-Tone closely matched that of the device alone & in each case unwanted throat deposition was reduced.
•Flo-Tone CR controls the resistance of the pMDI, thereby standardising the flow rate at which  
  Flo-Tone CR whistles
•Provide inhalation & coordination guidance
•Sounds (20-25 L/min)
•Drug delivery improvement = Therapeutic Improvement
•Less throat deposition – potentially less unwanted Throat Side-Effects
•Better control - less breakthrough – less SABA needed
•Better control – less hospitalisation 


• Spacer & Mask with anti-Microbial & anti-static properties
Collapsible – helps with storage & travel
• Visible valve movement - see that the drug is being Inhaled
• Suitable for adults & children
• Performance validated with pMDI’s
• Accepts all pMDI’s available
• Available with small & medium mask


• Ideal for emergency services use, schools & within General Practice & Hospitals for reversibility testing
• Single patient use
• Economical & environmentally friendly
• Performance validated with pMDI’s
• Available in bulk pack 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There have been many papers published, detailing the misuse of pMDI among patients;
Clement Clarke International have used their expertise to concentrate on this area of products. This
has led to the introduction of the ‘Inhaler Technique Training’ range. Each device is targeted at the
training of inhalation technique, guiding patients to inhale at the correct flow rate for pMDI use.
 
Inhaler technique errors occur in the hands of patients and healthcare professionals. It has been
demonstrated that the majority of healthcare professionals cannot demonstrate correct inhaler use
to their patients. It is not therefore surprising that patients are mostly unable to demonstrate good
inhaler technique. The consequences are significant; patients take higher doses to compensate for
lack of efficacy from medication lost through poor technique, this results in poorer control,
hospitalisation and increased healthcare costs.

The Clement Clarke ‘Inhaler Technique Training’ range delivers more reliable, more effective and patient friendly usage of medication and treatment (therapy) delivery.
Benefits summary
  • Patient friendly medication management and use
  • More effective and accurate delivery of medication to lungs
  • Reduced number of hospital admissions
  • Reduced number of un-planned clinical interventions
  • Reduced associated therapeutic costs
  • Improved patients’ health and quality of life
  • Available on the National Drug Tariff
  • Low cost devices
  • Available for immediate use
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The West Midlands region provides a great opportunity for rapid realisation of the benefits of improved inhaler training from a clinical, economic and patients’ quality of life perspectives.

All the required products and training materials are currently available for instant deployment and would offer significant benefits to those GP practices or secondary care providers willing to challenge existing ineffective training and delivery mechanisms and who would act as either the Regional or National adoption lead.
 
A comprehensive breakdown of the tools and devices required for a GP practice has been provided in an attached document (Essential Requirements for GP Practice Inhaler Training Kits).
Current and planned activity: 
Current NHS activity
Key areas of Contact are Lung Function & Respiratory Medicine which include Respiratory Physiologists & Respiratory Nurses both in Adults & Paediatrics.
 
Flo-Tone has been adopted by Wolverhampton CCG.

Planned/required activity
As a Manufacturer, Clement Clarke undertakes an extensive R&D program and also undertakes On-Site Clinical Trials with GP Practice & Secondary Care.
However, research and trials support partners would be welcomed to further develop the evidence base demonstrating the benefits of improved staff training with associated patient benefits.
In addition, Health Economic studies would also be welcomed to quantify the medication and admission cost savings that would be achieved. This would supplement the Isle of Wight study and include a wider geographical and ethnic / demographic patient cohort.
What is the intellectual property status of your innovation?:
All intellectual Property for devices and training is held by Clement Clarke International
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Anthony Silvio Philips 31/08/2016 - 10:46 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 08:33 Publish 1 comment
0
0
Votes
-99999

Recent Activities

Joanne Mewis commented on BMF 2 weeks 1 day ago
Joanne Mewis commented on BMF 2 weeks 1 day ago
Lucy Chatwin commented on Airglove: air warming system for venous access 12 weeks 10 hours ago
Lucy Chatwin voted on Airglove: air warming system for venous access 12 weeks 10 hours ago
Lucy Chatwin commented on Eye Hyper Tracking System - Eye Tracking Glasses 12 weeks 10 hours ago

Active Campaigns